Is cardiovascular disease a ‘pandemic hiding in plain sight’?Amarin’s Craig Granowitz discusses the impact of COVID on cardiovascular disease treatment and explains why there’s still a Share XIs cardiovascular disease a ‘pandemic hiding in plain sight’?https://pharmaphorum.com/views-and-analysis/is-cardiovascular-disease-a-pandemic-hiding-in-plain-sight/
NICE suggests lower threshold for hypertension treatmentThousands more patients could benefit from drugs and treatment for hypertension under new guidance from NICE, which has Share XNICE suggests lower threshold for hypertension treatmenthttps://pharmaphorum.com/news/nice-suggests-lower-threshold-for-hypertension-treatment-embargo/
Novartis licenses lipoprotein-lowering CVD drugExcited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment Share XNovartis licenses lipoprotein-lowering CVD drughttps://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/
